Trial Profile
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 Apr 2024
Price :
$35
*
At a glance
- Drugs Zanubrutinib (Primary) ; Ibrutinib
- Indications Chronic lymphocytic leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms ALPINE
- Sponsors BeiGene
- 17 Apr 2024 This trial has been completed in France, according to European Clinical Trials Database record.
- 28 Mar 2024 Status changed from active, no longer recruiting to completed.
- 25 Mar 2024 This trial has been completed in Sweden , according to European Clinical Trials Database record